Bellevue | Küsnacht, 11.01.2016.
The Nasdaq Biotech Index (NBI) ended the month of December up +1.3% in USD. BB Biotech’s NAV was up +0.2% in USD, -3.4% in CHF and down -3.0% in EUR. BB Biotech’s share price was up +2.6% in USD and lost -0.7% in EUR and -1.2% in CHF.
2015 was another year of outperformance for biotechnology versus general equity markets, with the Nasdaq Biotech Index NBI (+11.8% in USD) outperforming the S&P500 (+1.4% in USD) by +10%. BB Biotech AG closed the year up +28.2% (in USD), hence outperforming both its benchmark NBI and even more substantially the European indices such as the Swiss SMI (+1.1% in USD), the German DAX (-1.7% in USD) and the Euro Stoxx 600 (-0.9% in USD).